Compare Novartis with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs AUROBINDO PHARMA - Comparison Results

NOVARTIS     Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

AUROBINDO PHARMA 
   Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS AUROBINDO PHARMA NOVARTIS/
AUROBINDO PHARMA
 
P/E (TTM) x 2,126.1 18.7 11,399.7% View Chart
P/BV x 28.2 3.8 739.1% View Chart
Dividend Yield % 1.6 0.3 567.7%  

Financials

 NOVARTIS   AUROBINDO PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-19
AUROBINDO PHARMA
Mar-19
NOVARTIS/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs980830 118.1%   
Low Rs600527 113.9%   
Sales per share (Unadj.) Rs198.7333.9 59.5%  
Earnings per share (Unadj.) Rs21.040.4 52.0%  
Cash flow per share (Unadj.) Rs22.351.8 43.0%  
Dividends per share (Unadj.) Rs10.002.50 400.0%  
Dividend yield (eoy) %1.30.4 343.5%  
Book value per share (Unadj.) Rs307.5237.1 129.7%  
Shares outstanding (eoy) m24.69585.91 4.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.02.0 195.6%   
Avg P/E ratio x37.716.8 224.1%  
P/CF ratio (eoy) x35.513.1 270.8%  
Price / Book Value ratio x2.62.9 89.8%  
Dividend payout %47.76.2 769.9%   
Avg Mkt Cap Rs m19,508397,569 4.9%   
No. of employees `0000.617.9 3.3%   
Total wages/salary Rs m1,17125,849 4.5%   
Avg. sales/employee Rs Th8,445.410,956.9 77.1%   
Avg. wages/employee Rs Th2,015.71,447.7 139.2%   
Avg. net profit/employee Rs Th891.01,324.3 67.3%   
INCOME DATA
Net Sales Rs m4,907195,636 2.5%  
Other income Rs m7831,553 50.4%   
Total revenues Rs m5,689197,189 2.9%   
Gross profit Rs m12339,519 0.3%  
Depreciation Rs m326,680 0.5%   
Interest Rs m162,626 0.6%   
Profit before tax Rs m85831,767 2.7%   
Minority Interest Rs m027 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-881 0.0%   
Tax Rs m3407,269 4.7%   
Profit after tax Rs m51823,645 2.2%  
Gross profit margin %2.520.2 12.4%  
Effective tax rate %39.622.9 173.3%   
Net profit margin %10.612.1 87.3%  
BALANCE SHEET DATA
Current assets Rs m8,055153,645 5.2%   
Current liabilities Rs m1,850120,429 1.5%   
Net working cap to sales %126.417.0 744.7%  
Current ratio x4.41.3 341.2%  
Inventory Days Days45135 33.3%  
Debtors Days Days3464 53.2%  
Net fixed assets Rs m150103,909 0.1%   
Share capital Rs m123586 21.1%   
"Free" reserves Rs m7,469138,322 5.4%   
Net worth Rs m7,592138,908 5.5%   
Long term debt Rs m01,800 0.0%   
Total assets Rs m9,824264,544 3.7%  
Interest coverage x54.913.1 419.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.7 67.5%   
Return on assets %5.49.9 54.7%  
Return on equity %6.817.0 40.1%  
Return on capital %11.523.8 48.3%  
Exports to sales %049.6 0.0%   
Imports to sales %018.8 0.0%   
Exports (fob) Rs mNA97,091 0.0%   
Imports (cif) Rs mNA36,741 0.0%   
Fx inflow Rs m5897,316 0.1%   
Fx outflow Rs m1,32640,589 3.3%   
Net fx Rs m-1,26956,727 -2.2%   
CASH FLOW
From Operations Rs m-1,94316,220 -12.0%  
From Investments Rs m2,742-28,768 -9.5%  
From Financial Activity Rs m-29819,191 -1.6%  
Net Cashflow Rs m5016,656 7.5%  

Share Holding

Indian Promoters % 0.0 54.1 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 8.0 25.2%  
FIIs % 1.6 27.7 5.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.2 210.8%  
Shareholders   41,647 69,601 59.8%  
Pledged promoter(s) holding % 0.0 8.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  FDC LTD.  ASTRAZENECA PHARMA  BIOCON   

Compare NOVARTIS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Flat; Power and Telecom Stocks Witness Buying(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)

Jun 5, 2020 | Updated on Jun 5, 2020

For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY20); Net Profit Down 39.9% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, NOVARTIS has posted a net profit of Rs 77 m (down 39.9% YoY). Sales on the other hand came in at Rs 1 bn (down 13.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (3QFY20); Net Profit Down 0.5% (Quarterly Result Update)

Feb 7, 2020 | Updated on Feb 7, 2020

For the quarter ended December 2019, AUROBINDO PHARMA has posted a net profit of Rs 7 bn (down 0.5% YoY). Sales on the other hand came in at Rs 58 bn (up 10.1% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 4.6% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, AUROBINDO PHARMA has posted a net profit of Rs 6 bn (up 4.6% YoY). Sales on the other hand came in at Rs 56 bn (up 17.9% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Nov 6, 2019 | Updated on Nov 6, 2019

Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.

More Views on News

Most Popular

These 5 Smallcaps Deserve a Place in Your Coffee Can Portfolio(Profit Hunter)

Jul 28, 2020

When it comes to quality stocks, doing less is more.

Before You Buy Your First Electric Vehicle Consider Buying this Stock(Profit Hunter)

Jul 29, 2020

As competition intensifies in the electric vehicle space, only few will create huge wealth over the years.

Large Opportunities Are Coming Our Way

Aug 5, 2020

Kenneth Andrade tells us why stocks will bounce back strongly and what he's bullish on.

How to Buy Gold and Silver(Fast Profits Daily)

Jul 27, 2020

In this video I'll show you how to buy bullion the right way.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 7, 2020 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - STERLING BIOTECH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS